What’s Hot at ACC.26: Preview with Dr Latib & Prof Van Mieghem
-
1m 49s
-
4m
-
5m 39sPart 4 | Session 2 CHIP‑BCIS3 Trial: Impella Support in High‑Risk PCI
-
3m 10sPart 5 | Session 1 ORBITA‑CTO Trial: Sham‑Controlled CTO PCI Outcomes
-
2m 23sPart 5 | Session 2 ALL‑RISE & FAST III: FFRangio and vFFR vs Wire‑Based FFR in PCI Planning
-
2m 7sPart 5 | Session 3 OPTIMAL: Intravascular Imaging-Guided PCI in Complex Disease
-
1m 12sPart 5 | Session 4 IVUS-CHIP: Intravascular Ultrasound Guidance for High-Risk PCI
-
1m 39sPart 5 | Session 5 DKCRUSH‑VIII: IVUS‑Guided DK Crush in Complex Bifurcations
-
5m 45sPart 6 | Session 1 PRO‑TAVI Trial: Routine PCI vs Deferral in Patients Undergoing TAVI
-
4m 20sPart 6 | Session 2 Protect H2H Study: Head‑to‑Head Embolic Protection During TAVI
-
2m 59sPart 7 | Session 1 Tri.Fr Study: Transcatheter Tricuspid Repair
-
3m 14s
In this segment, Dr Azeem Latib and Prof Nicolas Van Mieghem take a closer look at HI‑PEITHO, a multinational, randomised trial comparing ultrasound‑facilitated, catheter‑directed thrombolysis with EkoSonic plus anticoagulation against anticoagulation alone in intermediate‑high‑risk pulmonary embolism (ClinicalTrials.gov: NCT04790370).
They walk through the key elements of the study design—patient selection based on RV dysfunction, positive troponin and clinical markers of imminent haemodynamic collapse, and the composite primary endpoint of PE‑related mortality, cardiorespiratory decompensation or collapse, and non‑fatal recurrent PE at 7 days.
What’s Hot at ACC.26: in this focused preview, Dr Azeem Latib (Montefiore Medical Center, US) and Prof Nicolas Van Mieghem, MD, PhD, pick out the late‑breaking clinical trials at ACC.26 that are most likely to influence practice for operators heading to New Orleans. In a fast, conversational format, they move from pulmonary embolism and left atrial appendage closure to heart failure, STEMI unloading, high‑risk PCI, and cerebral protection in TAVI, always coming back to what the designs, endpoints, and safety signals could mean for day‑to‑day decision‑making in the cath lab and structural heart program.
Produced by Radcliffe Cardiology, this ACC.26 late‑breaking clinical trials preview gives busy interventional and structural cardiologists a clear, opinion‑driven guide to the key data to watch; while our chaptered sections on the page let you dive deeper into each trial area as needed, and set the stage for our on‑site coverage from ACC.26.
Videographer: Mike Knight
Editor: Mirjam Boros
More from this programme
Part 1
ACC.26 Preview: Pulmonary embolism & catheter-directed therapy
In this opening chapter, interventional cardiologists Dr Azeem Latiband Prof Nicolas Van Mieghem explore how catheter‑directed therapy is changing the landscape in acute pulmonary embolism, from ultrasound‑facilitated thrombolysis to contemporary thrombectomy systems. They focus on which intermediate‑risk patients may genuinely benefit from an invasive strategy, balancing promising trial signals against uncertainties around hard outcomes, bleeding risk, and real‑world procedural logistics.
Part 2
ACC.26 Preview: Atrial fibrillation & LAAO
In this chapter, Dr Azeem Latib and Prof Nicolas Van Mieghem look at atrial fibrillation and left atrial appendage occlusion, centring on CHAMPION‑AF and what it could mean for when to choose WATCHMAN FLX over DOACs.
Part 3
ACC.26 Preview: Heart failure with preserved EF
In this chapter, Dr Azeem Latib and Prof Nicolas Van Mieghem briefly explore heart failure with preserved and mildly reduced ejection fraction, and what emerging evidence could mean for everyday treatment.
Part 4
ACC.26 Preview: Mechanical circulatory support
In this chapter, Dr Azeem Latib and Prof Nicolas Van Mieghem explore the evolving role of percutaneous left ventricular unloading in STEMI and high‑risk PCI, focusing on how current and upcoming trial data might reshape when operators reach for Impella support in daily practice.
Part 5
ACC.26 Preview: Complex PCI, physiology & imaging
In this chapter, Dr Azeem Latib and Prof Nicolas Van Mieghem, MD, PhD, turn to complex coronary intervention, discussing sham‑controlled CTO PCI, angiography‑based physiology tools, intravascular imaging‑guided PCI strategies and state‑of‑the‑art bifurcation stenting.
Part 6
TAVI strategy & cerebral protection
In this chapter Dr Azeem Latib and Prof Nicolas Van Mieghem turn to transcatheter aortic valve implantation, focusing on how best to manage coexistent coronary disease and how, when, and whether to use cerebral embolic protection. They use emerging data from strategy and device‑focused studies to frame what may actually change in everyday TAVI workflows.
Part 7
Tricuspid repair and replacement
In this chapter, Dr Azeem Latib, MD, and Prof Nicolas Van Mieghem discuss to the rapidly evolving field of transcatheter tricuspid interventions. They look at both repair and replacement strategies, highlighting how emerging data could change when heart teams move beyond medical therapy for patients with significant tricuspid regurgitation.
Faculty Biographies
Nicolas M Van Mieghem
Full Professor of Interventional Cardiology
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
Academic History
Prof. Nicolas M. Van Mieghem completed his medical training at the Catholic University of Leuven (Belgium), where he earned both his medical degree and his specialist degree in cardiology. During his time in Leuven, he developed a strong interest in cardiovascular medicine, particularly in the emerging field of minimally invasive cardiac interventions. After finishing his core medical and cardiology training, he pursued multiple advanced…
Azeem Latib
Section Head of Interventional Cardiology
Dr Mohamed Azeem Latib was born and raised in South Africa, where he also completed his early medical training. He later advanced his clinical and professional career internationally. He now resides in New York City, where he serves as the Section Head and Director of Interventional Cardiology and the Director of Structural Heart Interventions at the Montefiore-Einstein Center for Heart & Vascular Care. His career has spanned multiple countries and premier cardiovascular institutions.
Academic History
Dr Latib earned his Bachelor of Medicine, Bachelor of Surgery (MB BCh) from the University of the Witwatersrand in Johannesburg, South Africa, in 1995. He completed a fellowship with the College of Physicians of South Africa in 2002 and received his certificate in cardiology in 2005.
He pursued advanced subspecialty training in Europe, completing a Master’s degree in Interventional Cardiology at the San Raffaele Scientific Institute and University…
Comments